Company announcement – No. 37 / 2020
Following the registration of new shares in Zealand, Sunstone Life Science Ventures A/S controls less than 5% of the total voting rights in Zealand and Sunstone Life Science Ventures Fund I K/S holds less than 5% of the total share capital of Zealand.
Sunstone Life Science Ventures Fund I K/S (CVR no. 30589416) is managed by its general partner
For further information, please contact:
Zealand Pharma Investor Relations
+45 50 60 38 00
investors@zealandpharma.com
MDallas@zealandpharma.com
About
Zealand is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in
Zealand was founded in 1998 in
Attachment
- 37-20_0623_ZealandPharma_Major shareholder announcement
© OMX, source